Healthcare

Insurers like UnitedHealth may have to scale back benefits or raise prices, analysts say.

BlackRock’s Rieder is favored by traders to lead the Fed, healthcare stocks plunge, Polymarket scores another deal, and more news to start your day.

USA Rare Earth surges on a government investment, while CoreWeave jumps following an announcement that Nvidia is making a $2 billion investment in the AI cloud company.

Sarepta’s blockbuster gene therapy has come under scrutiny following a string of patient deaths.

Intel shares plummet following disappointing guidance, while rival AMD is poised to add to an eight-day winning streak.

The surgical robotics maker posts better-than-expected quarterly earnings as it begins rollout of cardiac procedures.

Venture Global, Miami International, and BillionToOne are among new stock issues that look appealing from a technical perspective.

Intel shares traded flat ahead of the chip maker’s fourth-quarter earnings, due out after the close of trading Thursday.

Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business flounders.

Abbott reports fourth-quarter sales that miss analysts’ estimates.

The CEOs of large health insurers testified Thursday on Capitol Hill amid a rising focus on healthcare costs.

Intel surges toward a four-year high ahead of earnings, while Netflix declines after issuing weaker-than-expected margin guidance.

The pharma giant’s shares rose 43% in 2025, making it their best year in three decades.

Each of the Magnificent Seven megacap stocks tumble as investors fret over President Donald Trump’s tariff threats.

Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.

Historically, small-cap stocks have soared or slumped. Now, after an unusually long period of underperformance, they’re showing some life.

Britain’s regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.

The shares have climbed on every trading day so far in 2026. The streak looks set to continue.

Taiwan companies offer U.S. chip investment for lower tariffs, Goldman sees possible opportunities in prediction markets, Verizon offering $20 credits after resolving service outage, and more news to start your day.

Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.

Investors aren’t concerned enough about China competition or a generic rival, UBS says.

The cash-and-stock acquisition values Penumbra at $374 a share.

Consumers should beware of skimpy, short-term insurance. Making these income moves may help you qualify for an Obamacare plan.

A look at the chart suggests that momentum is on its side.

The healthcare services company says it expects to bring in over $50 billion in specialty revenue in fiscal 2026.